prolgolimab   Click here for help

GtoPdb Ligand ID: 12991

Synonyms: BCD-100 | BCD100
Immunopharmacology Ligand
Compound class: Antibody
Comment: Prolgolimab (BCD-100) is a chimeric IgG1 anti-programmed cell death 1 (PD-1) monoclonal antibody [1]. It acts as an inhibitor of the PD-1/PD-L1-PD-L2 inhibitory immune checkpoint. The design of prolgolimab abolishes FcγR binding and therefore Fc-mediated effector functions (antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Prolgolimab (BCD-100) is in advanced clinical development for the treatment of advanced solid tumours. The fixed dose combination of prolgolimab (BCD-100) and nurulimab (BCD-145), BCD-217, has progressed to phase 3 clinical trials for advanced melanoma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03912389 Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC Phase 3 Interventional Biocad
NCT03912415 Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA) Phase 3 Interventional Biocad
NCT05732805 A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma Phase 3 Interventional Biocad
NCT03269565 International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma Phase 2 Interventional Biocad 2